UNITY color transp BG.jpg
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
June 21, 2023 07:00 ET | Unity Biotechnology, Inc.
Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks First novel...
UNITY color transp BG.jpg
UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
February 14, 2022 08:00 ET | Unity Biotechnology, Inc.
24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference   Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD)...
UNITY color transp BG.jpg
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
April 21, 2021 08:00 ET | Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases...
UNITY color transp BG.jpg
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates
March 23, 2021 16:01 ET | Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY color transp BG.jpg
UNITY Biotechnology to Participate in Upcoming March Investor Conferences
February 26, 2021 16:05 ET | Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
UNITY color transp BG.jpg
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
February 24, 2021 08:00 ET | Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
UNITY color transp BG.jpg
Study published in Cell Metabolism Reveals New Therapeutic Approach Aimed at Restoring Vascular Health and Reversing Age-Related Eye Disease
February 08, 2021 08:00 ET | Unity Biotechnology, Inc.
Study shows that senescent cells accumulate in the eye of patients with diabetic retinopathy, and elimination of these cells in preclinical models ameliorates disease Researchers at UNITY...
UNITY color transp BG.jpg
UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
February 01, 2021 08:00 ET | Unity Biotechnology, Inc.
Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz,...
UNITY color transp BG.jpg
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
September 15, 2020 08:00 ET | Unity Biotechnology, Inc.
- Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif., Sept. ...
UNITY color transp BG.jpg
UNITY Biotechnology to Participate in Upcoming September Investor Conferences
September 04, 2020 08:00 ET | Unity Biotechnology, Inc.
SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...